BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced full enrollment of the iliac artery patient cohort in its pivotal AGILITY Investigational Device ...
BD announced full enrollment of the iliac artery patient cohort in its pivotal AGILITY investigational device exemption (IDE) ...
BD (NYSE: BDX) today announced that it completed enrollment in the iliac artery patient cohort in its pivotal AGILITY study.
Becton Dickinson (BDX) announced full enrollment of the iliac artery patient cohort in its AGILITY investigational device ...
Background: A primary aortoenteric fistula (AEF) is a pathologic communication between the aorta and the gastrointestinal tract. Although uncommon, this condition carries a substantial risk of ...
A bioadaptor implant adaptable to vessel physiology was linked to less target lesion failure and target vessel failure ...
The REC-CAGEFREE I trial1 by Chao Gao and colleagues describes the results of a multicentre trial in which a paclitaxel drug-coated balloon (DCB) did not reach expected non-inferiority compared with a ...
UB neurosurgeon Elad Levy says the case proves complex endovascular procedures can be performed in outpatient neurosurgery ...
We deeply appreciate the feedback provided by Tingquan Zhou, Pitt O Lim, Christian Spaulding and colleagues, Filippo Luca Gurgoglione and Bernardo Cortese, and Tuomas T Rissanen and colleagues.
News-Medical.Net on MSN
Sirolimus-eluting balloon emerges as a safe and effective option for coronary in-stent restenosis
A new drug-eluting balloon can perform just as well as the standard treatment for patients with coronary in-stent restenosis ...
Dr. Kenneth Rosenfield discusses proficiencies required for performing transfemoral carotid artery stenting and how best to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback